Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs
Qing Liao, … , Yanqing Ding, Liang Zhao
Qing Liao, … , Yanqing Ding, Liang Zhao
Published April 3, 2025
Citation Information: J Clin Invest. 2025;135(11):e181243. https://doi.org/10.1172/JCI181243.
View: Text | PDF
Research Article Gastroenterology Immunology Oncology

Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs

  • Text
  • PDF
Abstract

Colorectal cancer (CRC) is characterized by an immune-suppressive microenvironment that contributes to tumor progression and immunotherapy resistance. The gut microbiome produces diverse metabolites that feature unique mechanisms of interaction with host targets, yet the role of many metabolites in CRC remains poorly understood. In this study, the microbial metabolite 4-hydroxybenzeneacetic acid (4-HPA) promoted the infiltration of PMN myeloid-derived suppressor cells (PMN-MDSCs) in the tumor microenvironment, consequently inhibiting the antitumor response of CD8+ T cells and promoting CRC progression in vivo. Mechanistically, 4-HPA activates the JAK2/STAT3 pathway, which upregulates CXCL3 transcription, thereby recruiting PMN-MDSCs to the CRC microenvironment. Selective knockdown of CXCL3 resensitized tumors to anti-PD-1 immunotherapy in vivo. Chlorogenic acid reduces the production of 4-HPA by microbiota, likewise abolishing 4-HPA–mediated immunosuppression. The 4-HPA content in CRC tissues was notably increased in patients with advanced CRC. Overall, the gut microbiome uses 4-HPA as a messenger to control chemokine-dependent accumulation of PMN-MDSC cells and regulate antitumor immunity in CRC. Our findings provide a scientific basis for establishing clinical intervention strategies to reverse the tumor immune microenvironment and improve the efficacy of immunotherapy by reducing the interaction among intestinal microbiota, tumor cells, and tumor immune cells.

Authors

Qing Liao, Ximing Zhou, Ling Wu, Yuyi Yang, Xiaohui Zhu, Hangyu Liao, Yujie Zhang, Weidong Lian, Feifei Zhang, Hui Wang, Yanqing Ding, Liang Zhao

×

Figure 4

The CXCL3/CXCR2 axis mediates MDSC recruitment and inhibits T-cell effector function.

Options: View larger image (or click on image) Download as PowerPoint
The CXCL3/CXCR2 axis mediates MDSC recruitment and inhibits T-cell effec...
(A) IF assays were performed to detect CXCR2 and Gr-1 in orthotopic cecal tumor of BALB/c mice. Scale bar: 50 μm. (B and C) The CXCL3-CXCR2 axis promoted the migratory abilities of MDSCs, as detected by transwell assays (n = 5). (D and E) Representative flow cytometry data show that MDSCs cells isolated from C57 mice inhibited cytokine and cytolytic granule production in CD8+T cells (D); the summarized result is presented in (E) (n = 5). (F) Effect of short hairpin Cxcl3 (sh-Cxcl3) and PD-1 immunotherapy on subcutaneous tumor of BALB/c mouse: CT26 subcutaneous tumors (n = 5). The CD279 anti–PD-1 antibody or isotype control (IgG) was i.p. injected three times daily (G and H) Tumor growth (G) and weight (H) were monitored (n = 5). Data represent the mean ± SD of 3 independent experiments. Statistical analyses were conducted using Student’s t test (2-comparison test) and 1-way ANOVA with Dunnett’s T3 correct multiple-comparison test. We used 2-way ANOVA to determine statistical significance of tumor volume. *P < 0.05; **P < 0.005; ***P < 0.0005.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts